02/22/2019
Opiant Pharmaceuticals, a specialty pharmaceutical company developing medicines for addictions and drug overdose, has halted its trial for a nasal spray designed to treat bulimia nervosa.
02/21/2019
Merck has agreed to buy Seattle-based biotechnology company, Immune Design, with the goal of improving vaccine development.
02/20/2019
The Federal Trade Commission has been cracking down on deals struck by brand-name drugmakers who pay off generics companies for postponing the release of lower-cost alternatives onto the market.
02/20/2019
The FDA has placed a partial hold on a phase 1 study into the study of a treatment for acute myeloid leukemia (AML).
02/19/2019
The expansion is expected to add 200 jobs in North Carolina, helping the drugmaker manufacture meds for rare genetic diseases
02/19/2019
The court's decision to reject Indivior's attempt to block copycats of its opioid addiction med is a win for generic drug maker Dr. Reddy's Laboratories
02/19/2019
The head of a small biotech firm had sharp words for the Pentagon over its lack of financial support for research into an experimental PTSD drug.
02/19/2019
A combination of treatments from Merck and Pfizer has shown to extend the life of patients with advanced kidney cancer.
02/18/2019
The U.S. FDA has announced new, efficient guidelines for the use of a novel pathway that provides incentives for developing generic versions of drugs that currently face little or no competition.
02/18/2019
Bayer has exercised its option, under a change-in-control clause in the collaboration agreement with Loxo Oncology, to obtain the exclusive licensing rights for the global development and commercialization of two cancer drugs.
